Halozyme Therapeutics to Engage in Key Investor Conferences in June 2025

Halozyme Prepares for Major Investor Conferences

Halozyme Therapeutics, Inc., a prominent player in the biopharmaceutical sector, is gearing up for a series of significant investor conferences that promise to highlight the company's innovative contributions to healthcare. Dr. Helen Torley, the President and CEO of Halozyme, is set to spearhead discussions and meetings designed to engage investors and stakeholders in the future of the company.

Conference Details

Halozyme's participation in these events underscores its commitment to transparency and communication with the investment community. The key details regarding its participation are as follows:

- Event: Benchmark 2025 Healthcare House Call Virtual Conference

Format: One-on-one Meetings
Date: Thursday, May 29, 2025

- Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Format: Fireside Chat and One-on-one Meetings
Date: Monday, June 9, 2025
Presentation Time: 7:00 AM PT / 10:00 AM ET

During the Goldman Sachs conference, a live audio webcast of Dr. Torley's presentation will be accessible in the Investor Relations section of Halozyme's website, with archived replays available for 90 days post-conference. These platforms offer investors a chance to gain insights into the company's strategic direction and potential growth opportunities in the biopharmaceutical landscape.

About Halozyme Therapeutics

Halozyme is at the forefront of advancing biopharmaceutical solutions that foster enhanced patient experiences and outcomes. Known for its pioneering ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20, Halozyme is revolutionizing how medications are administered. By facilitating subcutaneous delivery of drugs and fluids, the company aims to improve patient comfort and reduce treatment burdens significantly.

Halozyme's technology has made a substantial impact, contributing to the treatment of over one million patients through the commercialization of ten products in multiple global markets. The company has established partnerships for its ENHANZE® platform with several leading pharmaceutical and biotechnology entities, such as Roche, Takeda, Pfizer, and AbbVie, among others.

Continued Innovation and Growth

Beyond its delivery technology, Halozyme is actively involved in the development, manufacturing, and commercialization of drug-device combination products that leverage their advanced auto-injector technologies. These advancements focus on enhancing patient convenience and adherence, ensuring a seamless and efficient treatment process.

Currently, Halozyme features two proprietary products—Hylenex® and XYOSTED®—though the company is also engaged in collaborative product developments with partners like Teva Pharmaceuticals and McDermott Laboratories Limited. The ongoing pursuits of these projects are set to propel Halozyme into new areas of market growth and innovation.

As an organization headquartered in San Diego, California, Halozyme also operates offices in Ewing, New Jersey, and Minnetonka, Minnesota, where it houses its operations facility. The company's strategic positioning and scalability make it a compelling entity for investors looking to venture into the biopharmaceutical sector.

For further details on the upcoming conferences or to explore Halozyme's innovative product offerings, potential investors and interested parties can visit Halozyme's official website and connect on LinkedIn and Twitter for real-time updates.

With its continued focus on transformational healthcare solutions, Halozyme Therapeutics positions itself as a leader poised for substantial growth in the realm of biopharmaceutical advancements.